The study should prompt an “educational paradigm shift” in physicians to admit that antiplatelet agents are riskier than once thought, one expert says.

People in the region face a “double whammy” of worsening CV risk factors and, in some parts, ongoing violence.

There’s no “plateau,” suggests a registry analysis. As individual physician—not institutional—experience increases, TAVR outcomes improve.

In an analysis of over 500 hospitals, the quality of existing cardiac surgical care was indicative of TAVR program success.

Experts were not discouraged by the observational study, saying this is simply a reminder of the need for a large randomized trial—DanGer awaits.

A new bill released yesterday by the US House Ways and Means Committee would further postpone the 2.3% tax until 2025.

Dog owners are less likely to die after a cardiovascular event, but the reasons remain unclear.

Researchers are hopeful that imaging can help patients understand and perceive CVD risk better, which would lead to improved adherence.

Definitive evidence is lacking regarding potential CV effects, but preliminary evidence suggests some reason for concern.

In a year that has seen recall after recall for different ARBs, Mylan has announced a nationwide warning affecting more than 100 lots of medication.

Experts are calling for more randomized studies to confirm the mechanism by which ARBs and ACE inhibitors might help patients with aortic stenosis.